Navid Rabiee, Ph.D., is a Postdoctoral research associate at the Sharif University of Technology, Tehran, Iran, and an Invited Visiting Scholar at Macquarie University, Sydney, New South Wales, Australia. Since 2016, he is working on several fields with a multidisciplinary approach by blending modern molecular and cellular biology/biochemical sciences with engineering principles to design the next generation of medical systems and devices for patient treatment. He is a pioneer in the field of BioInorganic Chemistry with an emphasis on CRISPR delivery with the assistance of inorganic nano-vectors. His work has resulted in the publication of over 200 peer-reviewed journal articles in prestigious journals, including?Nature,?Nature Medicine,?The Lancet,?Nano Today, Biomaterials, Advanced Functional Materials?and etc., 6 books, over 20 chapters and 5 conference papers Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors.

• Section I: Nanomedicine and cancer 1. Cancer therapy challenges 2. Development of therapy resistance in cancer 3. An overview of oncogenic and onco-suppressor pathways in cancer 4. Role of nanomedicine in cancer therapy: Promising and opportunities 5. Optimization, design and development of nanostructures for purpose of cancer therapy: Principles of cargo loading and exploring new emerging platforms Section II: Gastrointestinal tumors: Pathogenesis and progression 6. Gastric cancer: Epidemiology, pathogenesis and progression factors 7: Liver cancer: Epidemiology, pathogenesis and progression factors 8. Colorectal cancer: Epidemiology, pathogenesis and progression factors 9. Pancreatic cancer: Epidemiology, pathogenesis and progression factors 10. Esophageal cancer: Epidemiology, pathogenesis and progression factors Section III: Nanomedicine and gastric cancer 11. Polymeric nanoparticles in gastric cancer therapy 12. Lipid-based nanoparticles in gastric cancer therapy 13. Carbon-based nanoparticles in gastric cancer therapy 14. Metal-based nanoparticles in gastric cancer therapy Section IV: Nanomedicine and liver cancer 15. Polymeric nanoparticles in liver cancer therapy 16. Lipid-based nanoparticles in liver cancer therapy 17. Carbon-based nanoparticles in liver cancer therapy 18. Metal-based nanoparticles in liver cancer therapy Section V: Nanomedicine and Colorectal cancer Chapter 18: Polymeric nanoparticles in gastric cancer therapy 19. Lipid-based nanoparticles in gastric cancer therapy 20. Carbon-based nanoparticles in gastric cancer therapy Chapter 21: Metal-based nanoparticles in gastric cancer therapy Section VI: Nanomedicine and pancreatic cancer 21. Polymeric nanoparticles in gastric cancer therapy 22. Lipid-based nanoparticles in gastric cancer therapy 23. Carbon-based nanoparticles in gastric cancer therapy 24. Metal-based nanoparticles in gastric cancer therapy Chapter VII: Nanomedicine and esophageal cancer 25. An overview of nanostructures in esophageal cancer therapy

Navid Rabiee, Ph.D., is a Postdoctoral research associate at the Sharif University of Technology, Tehran, Iran, and an Invited Visiting Scholar at Macquarie University, Sydney, New South Wales, Australia. Since 2016, he is working on several fields with a multidisciplinary approach by blending modern molecular and cellular biology/biochemical sciences with engineering principles to design the next generation of medical systems and devices for patient treatment. He is a pioneer in the field of BioInorganic Chemistry with an emphasis on CRISPR delivery with the assistance of inorganic nano-vectors. His work has resulted in the publication of over 200 peer-reviewed journal articles in prestigious journals, including?Nature,?Nature Medicine,?The Lancet,?Nano Today, Biomaterials, Advanced Functional Materials?and etc., 6 books, over 20 chapters and 5 conference papers Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors.

• Section I: Nanomedicine and cancer 1. Cancer therapy challenges 2. Development of therapy resistance in cancer 3. An overview of oncogenic and onco-suppressor pathways in cancer 4. Role of nanomedicine in cancer therapy: Promising and opportunities 5. Optimization, design and development of nanostructures for purpose of cancer therapy: Principles of cargo loading and exploring new emerging platforms Section II: Gastrointestinal tumors: Pathogenesis and progression 6. Gastric cancer: Epidemiology, pathogenesis and progression factors 7: Liver cancer: Epidemiology, pathogenesis and progression factors 8. Colorectal cancer: Epidemiology, pathogenesis and progression factors 9. Pancreatic cancer: Epidemiology, pathogenesis and progression factors 10. Esophageal cancer: Epidemiology, pathogenesis and progression factors Section III: Nanomedicine and gastric cancer 11. Polymeric nanoparticles in gastric cancer therapy 12. Lipid-based nanoparticles in gastric cancer therapy 13. Carbon-based nanoparticles in gastric cancer therapy 14. Metal-based nanoparticles in gastric cancer therapy Section IV: Nanomedicine and liver cancer 15. Polymeric nanoparticles in liver cancer therapy 16. Lipid-based nanoparticles in liver cancer therapy 17. Carbon-based nanoparticles in liver cancer therapy 18. Metal-based nanoparticles in liver cancer therapy Section V: Nanomedicine and Colorectal cancer Chapter 18: Polymeric nanoparticles in gastric cancer therapy 19. Lipid-based nanoparticles in gastric cancer therapy 20. Carbon-based nanoparticles in gastric cancer therapy Chapter 21: Metal-based nanoparticles in gastric cancer therapy Section VI: Nanomedicine and pancreatic cancer 21. Polymeric nanoparticles in gastric cancer therapy 22. Lipid-based nanoparticles in gastric cancer therapy 23. Carbon-based nanoparticles in gastric cancer therapy 24. Metal-based nanoparticles in gastric cancer therapy Chapter VII: Nanomedicine and esophageal cancer 25. An overview of nanostructures in esophageal cancer therapy

Navid Rabiee, Ph.D., is a Postdoctoral research associate at the Sharif University of Technology, Tehran, Iran, and an Invited Visiting Scholar at Macquarie University, Sydney, New South Wales, Australia. Since 2016, he is working on several fields with a multidisciplinary approach by blending modern molecular and cellular biology/biochemical sciences with engineering principles to design the next generation of medical systems and devices for patient treatment. He is a pioneer in the field of BioInorganic Chemistry with an emphasis on CRISPR delivery with the assistance of inorganic nano-vectors. His work has resulted in the publication of over 200 peer-reviewed journal articles in prestigious journals, including?Nature,?Nature Medicine,?The Lancet,?Nano Today, Biomaterials, Advanced Functional Materials?and etc., 6 books, over 20 chapters and 5 conference papers Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors.

• Section I: Nanomedicine and cancer 1. Cancer therapy challenges 2. Development of therapy resistance in cancer 3. An overview of oncogenic and onco-suppressor pathways in cancer 4. Role of nanomedicine in cancer therapy: Promising and opportunities 5. Optimization, design and development of nanostructures for purpose of cancer therapy: Principles of cargo loading and exploring new emerging platforms Section II: Gastrointestinal tumors: Pathogenesis and progression 6. Gastric cancer: Epidemiology, pathogenesis and progression factors 7: Liver cancer: Epidemiology, pathogenesis and progression factors 8. Colorectal cancer: Epidemiology, pathogenesis and progression factors 9. Pancreatic cancer: Epidemiology, pathogenesis and progression factors 10. Esophageal cancer: Epidemiology, pathogenesis and progression factors Section III: Nanomedicine and gastric cancer 11. Polymeric nanoparticles in gastric cancer therapy 12. Lipid-based nanoparticles in gastric cancer therapy 13. Carbon-based nanoparticles in gastric cancer therapy 14. Metal-based nanoparticles in gastric cancer therapy Section IV: Nanomedicine and liver cancer 15. Polymeric nanoparticles in liver cancer therapy 16. Lipid-based nanoparticles in liver cancer therapy 17. Carbon-based nanoparticles in liver cancer therapy 18. Metal-based nanoparticles in liver cancer therapy Section V: Nanomedicine and Colorectal cancer Chapter 18: Polymeric nanoparticles in gastric cancer therapy 19. Lipid-based nanoparticles in gastric cancer therapy 20. Carbon-based nanoparticles in gastric cancer therapy Chapter 21: Metal-based nanoparticles in gastric cancer therapy Section VI: Nanomedicine and pancreatic cancer 21. Polymeric nanoparticles in gastric cancer therapy 22. Lipid-based nanoparticles in gastric cancer therapy 23. Carbon-based nanoparticles in gastric cancer therapy 24. Metal-based nanoparticles in gastric cancer therapy Chapter VII: Nanomedicine and esophageal cancer 25. An overview of nanostructures in esophageal cancer therapy